A mutation in the BRAF oncogene, BRAF V600E, has been linked to the most common type of tyroid cancer, conventional papillary thyroid cancer or PTC.

A new study shows that this mutation is also significantly associated with cancer recurrence after treatment, according to Dr. Electron Kebebew at UCSF.


Most patients diagnosed wtih PTC have small, localized PTC, but may receive aggressive treatments becasue their risk of recurrence cannot be predicted before surgery.

According to the researchers, this result shows that this particular mutation is a reliable indicator for recurrence likelihood and testing for the mutation may be useful for selecting the initial therapy.


Source: TheCancerBlog